Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralesional Triamcinolone for Hidradenitis Suppurativa
NCT02781818Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2016
- Primary completion
- Jun 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of triamcinolone in hidradenitis suppurativa (HS) (3 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Number of Days to Lesion Resolution in Combined Treatment Arms Compared to the Placebo Arm. Started Jun 2016; status: completed.
02
Drugs
triamcinolone
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT02781818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781818.